Chronic headache education and self-management study (CHESS)

Conditions

Chronic headaches Signs and Symptoms Chronic headaches

Vivien Nichols, David R Ellard, Frances Griffiths, Martin Underwood, Kirstie Haywood et al. (25 authors)

BMC Neurology2024-08-024 citations

Does pain self-efficacy predict, moderate or mediate outcomes in people with chronic headache; an exploratory analysis of the CHESS trial

Siew Wan Hee, Shilpa Patel, Harbinder Sandhu, Manjit Matharu, Martin Underwood et al. (28 authors)

The Journal of Headache and Pain2024-05-147 citations

10.1186/s10194-024-01768-5

Non-pharmacological educational and self-management interventions for people with chronic headache: the CHESS research programme including a RCT

Martin Underwood, Felix Achana, Dawn Carnes, Sandra Eldridge, David R Ellard et al. (23 authors)

Programme Grants for Applied Research2023-06-019 citations

10.3310/pljl1440

Chronic Headache Education and Self-Management Study (CHESS): a process evaluation

David R Ellard, Vivien Nichols, Frances Griffiths, Martin Underwood, Stephanie Taylor et al. (28 authors)

BMC Neurology2023-01-077 citations

10.1186/s12883-022-02792-1

Supportive Self-Management Program for People With Chronic Headaches and Migraine: A Randomized Controlled Trial and Economic Evaluation.

Underwood M, Achana F, Carnes D, Eldridge S, Ellard DR, Griffiths F, Haywood K, Hee SW, Higgins H, Mistry D, Mistry H, Newton S, Nichols V, Norman C, Padfield E, Patel S, Petrou S, Pincus T, Potter R, Sandhu H, Stewart K, Taylor SJC, Matharu MS.

2022-12-1615 citations

10.1212/wnl.0000000000201518

Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)

Kirstie Haywood, Felix Achana, Vivien Nichols, Gemma Pearce, Barbara Box et al. (12 authors)

Cephalalgia2021-05-0423 citations

10.1177/03331024211006045

Usual care and a self-management support programme versus usual care and a relaxation programme for people living with chronic headache disorders: a randomised controlled trial protocol (CHESS)

Shilpa Patel, Felix Achana, Dawn Carnes, Sandra Eldridge, David R Ellard et al. (19 authors)

BMJ Open2020-04-0121 citations

10.1136/bmjopen-2019-033520

The CHESS trial: protocol for the process evaluation of a randomised trial of an education and self-management intervention for people with chronic headache.

Nichols VP, Ellard DR, Griffiths FE, Underwood M, Taylor SJC, Patel S, CHESS team.

2019-06-045 citations

10.1186/s13063-019-3372-x

Development of an education and self-management intervention for chronic headache - CHESS trial (Chronic Headache Education and Self-management Study).

Patel S, Potter R, Matharu M, Carnes D, Taylor SJC, Nichols V, Pincus T, Underwood M, Sandhu H, CHESS team.

2019-03-1816 citations

10.1186/s10194-019-0980-5

Chronic Headache Education and Self-management Study (CHESS) – a mixed method feasibility study to inform the design of a randomised controlled trial

Kimberley White, Rachel Potter, Shilpa Patel, Vivien Nichols, Kirstie Haywood et al. (12 authors)

BMC Medical Research Methodology2019-02-1115 citations

10.1186/s12874-019-0672-5

Interventions

Feasibility study: An education and self-management support intervention for the management of chronic headaches, specifically, migraine, TTH and MOH will be designed and evaluated. The design of the

tension type headache, probable chronic migraine and definite chronic migraine with or without medication overuse headache) using randomly permuted blocks, and implemented using a remote, independent

Eligibility

Sex/Gender

All

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: 1. Able and willing to comply with the study procedures and provision of written informed consent 2. Aged 18 years or above 3. Living with chronic headache; defined as headache for 15 or more days per month for at least three months. 4. Result of nurse classification interview confirms headache type to be definite or probable chronic migraine, or chronic tension type headache, and/or medication overuse headache 5. Fluent in written and spoken English

Exclusion criteria

Exclusion criteria: 1. Unable to attend treatment programme 2. No access to a telephone 3. Has an underlying serious psychiatric or psychological disorder that precludes participation in the group intervention 4. Known secondary cause of headache other than medication overuse headache; e.g. primary or secondary brain tumour 5. Is currently participating in another clinical trial (with an unregistered medicinal product), or less than 90 days have passed since completing participation in such a trial

Design outcomes

Primary

Measure	Time frame
Primary outcome measures as of 04/05/2017: Feasibility study: Headache impact measured using the Headache Impact Test (HIT-6) as a self-complete postal questionnaire at baseline, 2 weeks and 12 weeks. Randomised controlled trial: Headache impact measured using the Headache Impact Test (HIT-6) as a self-complete postal questionnaire at baseline, 4, 8 and 12 months Original Primary outcome measure: Headache specific outcome measure collected by self-completed postal questionnaire.	—

Measure

Time frame

Primary outcome measures as of 04/05/2017: Feasibility study: Headache impact measured using the Headache Impact Test (HIT-6) as a self-complete postal questionnaire at baseline, 2 weeks and 12 weeks. Randomised controlled trial: Headache impact measured using the Headache Impact Test (HIT-6) as a self-complete postal questionnaire at baseline, 4, 8 and 12 months Original Primary outcome measure: Headache specific outcome measure collected by self-completed postal questionnaire.

—

Secondary

Measure	Time frame
Feasibility study: 1. Migraine Disability measured using the Migraine Disability Assessment (MIDAS) as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 2. Health related quality of life measured using the 12-Item Short Form Health Survey (SF-12) - at baseline, 2 weeks and 12 weeks 3. Mood measured using the Hospital Anxiety and Depression Scale at as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 4. Self –efficacy measured using the Self-efficacy and Pain Self –Efficacy Questionnaire as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 5. Headache quality of life measured using Chronic Headache Quality of Life Questionnaire (CHQLQ) a headache-specific modification of the Migraine Specific Quality of Life Questionnaire (MSQ) completed as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 6. Health utility measured using EQ-5D as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 7. Social activity measured using the Health Education Impact Questionnaire (Social Integration sub-scale) as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 8. Health service activity measured as self-complete questionnaire: GP consultations, secondary care consultations, imaging, non-NHS treatments (e.g. acupuncture), over-the-counter medication for headaches, days lost from normal activities (e.g. work, study), loss of income and out of pocket expenses completed at baseline, 2 weeks and 12 weeks 9. Headache frequency, duration and severity measured via a smartphone App weekly for 12 weeks 10. Health service activity; consultations, outpatient appointments, imaging and medication use of acute and prophylactic headache treatments collected from GP records at 3 months Randomised controlled trial: 1. Participant demographic data completed as a self-complete questionnaire at baseline 2. General Health including fatigue, sleep quality and bodily pain measured by the troublesomeness grid as a self-complete	—

Measure

Time frame

Feasibility study: 1. Migraine Disability measured using the Migraine Disability Assessment (MIDAS) as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 2. Health related quality of life measured using the 12-Item Short Form Health Survey (SF-12) - at baseline, 2 weeks and 12 weeks 3. Mood measured using the Hospital Anxiety and Depression Scale at as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 4. Self –efficacy measured using the Self-efficacy and Pain Self –Efficacy Questionnaire as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 5. Headache quality of life measured using Chronic Headache Quality of Life Questionnaire (CHQLQ) a headache-specific modification of the Migraine Specific Quality of Life Questionnaire (MSQ) completed as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 6. Health utility measured using EQ-5D as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 7. Social activity measured using the Health Education Impact Questionnaire (Social Integration sub-scale) as a self-complete questionnaire at baseline, 2 weeks and 12 weeks 8. Health service activity measured as self-complete questionnaire: GP consultations, secondary care consultations, imaging, non-NHS treatments (e.g. acupuncture), over-the-counter medication for headaches, days lost from normal activities (e.g. work, study), loss of income and out of pocket expenses completed at baseline, 2 weeks and 12 weeks 9. Headache frequency, duration and severity measured via a smartphone App weekly for 12 weeks 10. Health service activity; consultations, outpatient appointments, imaging and medication use of acute and prophylactic headache treatments collected from GP records at 3 months Randomised controlled trial: 1. Participant demographic data completed as a self-complete questionnaire at baseline 2. General Health including fatigue, sleep quality and bodily pain measured by the troublesomeness grid as a self-complete

—

Countries

England, United Kingdom

Contacts

Public ContactTrial Team

Ctuenquiries@warwick.ac.uk-

Outcome results

None listed